AzTrials
AzTrials

Congenital Adrenal HyperplasiaNCT04903587

Gonadal Changes In Congenital Adrenal Hyperplasia Patients

An observational study of Congenital Adrenal Hyperplasia, run by Ain Shams University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

To detect the prevalence of gonadal changes by US among the patients with CAH. assess the patients' radiological findings in relation to their hormonal profile. early management and prevention of complications resulting from possible gonadal dysfunction. Read more about this study

Who is it for?
Ages 5 to 16 years
Conditions the study is for
Congenital Adrenal Hyperplasia
What is being tested?
Ultrasonography and MRI
Type of treatment
Medical device
How many people
50 participants
Where
1 siteEgypt
Study dates
1 Oct 2021to Nov 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 5 to 16 years
  • All sexes
  • Child

Study population: all patients diagnosed with congenital adrenal hyperplasia (CAH)

Who may be able to join

  • All patients diagnosed with CAH between five and 16 years of age will be asked to participate in this cross sectional study.
  • Compliant patients with regular follow up.

Who cannot join

  • Presence of other endocrinal diseases or chronic conditions.
  • Female patients with ovulatory dysfunction from other causes including thyroid dysfunction and hyperprolactinemia.
  • Male patients with other diseases causing impairment of gonadal capacity.

Trial locations and contacts

1 site in 1 country.

Hasnaa Hassan, post gradute contact

01000748134

dr.hmm28@gmail.com

Mohamed Salah Elkholy, professor contact

01005838888

Egypt1 site, 1 recruiting
  • Ain Shams University

    Cairo

    Hasnaa Hassan Mohammed, 01000748134, dr.hmm28@gmail.com

    Rana Abdelhakim Ahmed, 01115006946, dr.ranahakim@gmail.com

    Recruiting

Other trials in Egypt

About this study

Official title: The Prevalence Of Gonadal Changes In Patients With Congenital Adrenal Hyperplasia

To detect the prevalence of gonadal changes by US among the patients with CAH.

  • assess the patients' radiological findings in relation to their hormonal profile.
  • early management and prevention of complications resulting from possible gonadal dysfunction.
Read the detailed description

Several factors contribute to the impaired fertility in CAH patients, such as androgen excess, adrenal progesterone hypersecretion and adrenal rest tumours (ARTs). ARTs are derived from ectopic adrenal cells that migrated to the gonads in foetal life, and their growth is under control of adrenocorticotropic hormone (ACTH) and angiotensin II .

The common cause of infertility in males with CAH is testicular adrenal rest tumours (TARTs) , which have been well documented in CAH male patients, with an incidence up to 94%. They could be easily imaged by US and MRI studies. TARTs are associated with the risk of seminal duct obstruction, leading to azoospermia and permanent damage of the surrounding testicular tissue. TARTs can present as single nodules , and as multiple nodules in 16% of patients. Increasing the dosage of hormone therapy can cause early TARTs lesions to shrink or completely resolve, while advanced lesions may require surgical removal .

High prevalence of impaired fertility is not restricted to men; as it was reported also in women with CAH. Androgen excess is usually implicated in girls and women with CAH for whom medical treatment is unavailable or who are noncompliant with their therapy . Adrenal androgens act either directly or through the dysfunction caused at the hypothalamic pituitary axis. Interestingly, ovarian hyperandrogenism could occur even when CAH is well controlled on glucocorticoid therapy .

Females with CAH may become infertile for several reasons, such as chronic anovulation, which was demonstrated in up to 50% of the patients with non-classic CAH . Bilateral enlarged ovaries, bilateral ovarian cysts, and ovarian adrenal rest tumour (OART) may also occur and can be detected by US. OART impairs ovarian function in CAH females by displacing normal ovarian tissue and by locally producing steroids, which interfere with normal ovarian function. It should be considered when ovarian masses are detected. If detected early enough and glucocorticoid therapy is received, it is possible that it will decrease in size following suppression of ACTH levels. Polycystic ovary syndrome (PCOS) is another common condition associated with hyperandrogenism. The prevalence of PCOS is increased in women with both classical and non-classical CAH. The association of CAH with ultrasonically detected PCOS was confirmed in 83%, 40% and 3% of the adult patients, postpubertal girls and pre and peripubertal girls respectively .

Under treatment of ARTs, PCOS and other gonadal comorbidities negatively influences the quality of life as well as sexual outcomes in patients with CAH. Besides, recognizing these conditions and identifying characteristic US features of gonadal dysfunction is important, so as to avoid misdiagnosing them as malignancies, which can lead to unnecessary interventions.

Being tested
Ultrasonography and MRI
Medical subject headings
Adrenal Hyperplasia, Congenital

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultrasonography and MRIDevice

    Abdominal Ultrasonography and axial MRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. prevalence of gonadal changes in CAH patients

    By using US and MRI to detect the finding in gonades in CAH patients

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 May 2021
  2. Study start1 Oct 2021
  3. Primary completionOct 2022 (estimated)
  4. Study completionNov 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04903587
Sponsor's protocol ID
US and MRI in CAH patients
Status last verified
May 2021
First submitted
23 May 2021
Last updated
30 Dec 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Dumic M, Duspara V, Grubic Z, Oguic SK, Skrabic V, Kusec V. Testicular adrenal rest tumors in congenital adrenal hyperplasia-cross-sectional study of 51 Croatian male patients. Eur J Pediatr. 2017 Oct;176(10):1393-1404. doi: 10.1007/s00431-017-3008-7. Epub 2017 Sep 6.

    PubMed 28879515
  • Chen HD, Huang LE, Zhong ZH, Su Z, Jiang H, Zeng J, Liu JC. Ovarian Adrenal Rest Tumors Undetected by Imaging Studies and Identified at Surgery in Three Females with Congenital Adrenal Hyperplasia Unresponsive to Increased Hormone Therapy Dosage. Endocr Pathol. 2017 Jun;28(2):146-151. doi: 10.1007/s12022-016-9461-4.

    PubMed 28032206

Questions about this trial

What is this clinical trial studying?

An observational study of Congenital Adrenal Hyperplasia, run by Ain Shams University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Hasnaa Hassan, post gradute (01000748134, dr.hmm28@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

prevalence of gonadal changes in CAH patients (time frame: baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04903587, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in